ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'Emerging role for sphingolipids in the genetics of amyotrophic lateral sclerosis', Journal of Neurology, Neurosurgery and Psychiatry, 95, pp. 101 - 102, http://dx.doi.org/10.1136/jnnp-2023-332719
,2023, 'Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia', Clinical Neurophysiology, 154, pp. 157 - 168, http://dx.doi.org/10.1016/j.clinph.2023.08.002
,2023, 'Imbalance and lower limb tremor in chronic inflammatory demyelinating polyradiculoneuropathy', Journal of the Peripheral Nervous System, 28, pp. 415 - 424, http://dx.doi.org/10.1111/jns.12574
,2023, 'Presymptomatic spinal muscular atrophy: a cautionary approach to the proposed new terminology', Brain, 146, pp. E65 - E66, http://dx.doi.org/10.1093/brain/awad061
,2023, 'Survival in sporadic ALS is associated with lower p62 burden in the spinal cord', Journal of Neuropathology and Experimental Neurology, 82, pp. 769 - 773, http://dx.doi.org/10.1093/jnen/nlad051
,2023, 'Cortical hyperexcitability in amyotrophic lateral sclerosis: from pathogenesis to diagnosis', Current Opinion in Neurology, 36, pp. 353 - 359, http://dx.doi.org/10.1097/WCO.0000000000001162
,2023, 'Hyperexcitability, neurodegeneration, and disease progression in amyotrophic lateral sclerosis', Muscle and Nerve, 68, pp. 103 - 105, http://dx.doi.org/10.1002/mus.27843
,2023, 'Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS', Neuropathology and Applied Neurobiology, 49, http://dx.doi.org/10.1111/nan.12919
,2023, 'UNC13A in amyotrophic lateral sclerosis: From genetic association to therapeutic target', Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 649 - 656, http://dx.doi.org/10.1136/jnnp-2022-330504
,2023, 'Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee', Clinical Neurophysiology, 150, pp. 131 - 175, http://dx.doi.org/10.1016/j.clinph.2023.03.010
,2023, 'Dependence of cortical neuronal strength-duration properties on TMS pulse shape', Clinical Neurophysiology, 150, pp. 106 - 118, http://dx.doi.org/10.1016/j.clinph.2023.03.012
,2023, 'Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension', eClinicalMedicine, 60, http://dx.doi.org/10.1016/j.eclinm.2023.102036
,2023, 'Strength-duration properties and excitability of motor and sensory axons across different target thresholds', Journal of Neurophysiology, 129, pp. 1434 - 1446, http://dx.doi.org/10.1152/jn.00456.2022
,2023, 'The lower motor neuron homunculus: function matters', Brain, 146, pp. E34 - E35, http://dx.doi.org/10.1093/brain/awad021
,2023, 'Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.ade2044
,2023, 'Cortical inhibition and facilitation are mediated by distinct physiological processes', Neuroscience Letters, 803, http://dx.doi.org/10.1016/j.neulet.2023.137191
,2023, 'Neurotoxic risks from over-the-counter vitamin supplements', Medical Journal of Australia, 218, pp. 304 - 306, http://dx.doi.org/10.5694/mja2.51851
,2023, 'Chronic inflammatory demyelinating polyradiculoneuropathy-associated tremor: Phenotype and pathogenesis', European Journal of Neurology, 30, pp. 1059 - 1068, http://dx.doi.org/10.1111/ene.15693
,2023, 'Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis', Brain, 146, pp. E17 - E19, http://dx.doi.org/10.1093/brain/awac467
,2023, 'Consensus for experimental design in electromyography (CEDE) project: Single motor unit matrix', Journal of Electromyography and Kinesiology, 68, http://dx.doi.org/10.1016/j.jelekin.2022.102726
,2023, 'Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review', Journal of Cancer Survivorship, 17, pp. 222 - 236, http://dx.doi.org/10.1007/s11764-021-00988-x
,2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074
,2023, 'Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24, pp. 14 - 23, http://dx.doi.org/10.1080/21678421.2022.2053721
,2023, 'Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis', Muscle and Nerve, 67, pp. 17 - 24, http://dx.doi.org/10.1002/mus.27736
,2023, 'Diagnostic utility of transcranial magnetic stimulation for neurodegenerative disease: a critical review', Dementia e Neuropsychologia, 17, http://dx.doi.org/10.1590/1980-5764-DN-2023-0048
,2023, 'Distinct hypothalamic involvement in the amyotrophic lateral sclerosis-frontotemporal dementia spectrum', NeuroImage: Clinical, 37, http://dx.doi.org/10.1016/j.nicl.2022.103281
,2023, 'Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis', Brain Communications, 5, http://dx.doi.org/10.1093/braincomms/fcac340
,2023, 'Nanocrystalline gold (CNM-Au8): a novel bioenergetic treatment for ALS', Expert Opinion on Investigational Drugs, 32, pp. 783 - 785, http://dx.doi.org/10.1080/13543784.2023.2263368
,2023, 'N°51 – Phenotype and pathogenesis of upper limb tremor in CIDP', Clinical Neurophysiology, 150, pp. e88 - e88, http://dx.doi.org/10.1016/j.clinph.2023.03.060
,2022, 'Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1', Genome Medicine, 14, http://dx.doi.org/10.1186/s13073-021-01006-6
,2022, 'Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial', Trials, 23, http://dx.doi.org/10.1186/s13063-022-06906-5
,2022, 'The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review', Neuropathology and Applied Neurobiology, 48, http://dx.doi.org/10.1111/nan.12845
,2022, 'A Systematic Review of Caregiver Coping Strategies in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia', Journal of Geriatric Psychiatry and Neurology, 35, pp. 763 - 777, http://dx.doi.org/10.1177/08919887211060016
,2022, 'Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use', Quality of Life Research, 31, pp. 3091 - 3107, http://dx.doi.org/10.1007/s11136-022-03154-7
,2022, 'Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia', Muscle and Nerve, 66, pp. 576 - 582, http://dx.doi.org/10.1002/mus.27698
,2022, 'Hyperexcitability and ALS', Journal of Neurology, Neurosurgery and Psychiatry, 93, pp. 1027, http://dx.doi.org/10.1136/jnnp-2021-328756
,2022, 'Brainspotting: Adventures in Neurology', Journal of neurology, neurosurgery, and psychiatry, 93, pp. 800 - 801, http://dx.doi.org/10.1136/jnnp-2022-329455
,2022, 'Electrodiagnostic findings in facial onset sensory motor neuronopathy (FOSMN)', Clinical Neurophysiology, 140, pp. 228 - 238, http://dx.doi.org/10.1016/j.clinph.2022.04.020
,2022, 'NEK1 and STMN2 short tandem repeat lengths are not associated with Australian amyotrophic lateral sclerosis risk', Neurobiology of Aging, 116, pp. 92 - 95, http://dx.doi.org/10.1016/j.neurobiolaging.2022.04.012
,2022, 'Schizotypal traits across the amyotrophic lateral sclerosis–frontotemporal dementia spectrum: pathomechanistic insights', Journal of Neurology, 269, pp. 4241 - 4252, http://dx.doi.org/10.1007/s00415-022-11049-3
,2022, 'Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 30, pp. 5965 - 5974, http://dx.doi.org/10.1007/s00520-022-07024-3
,2022, 'Letter to the Editor re "Complete Foot Drop With Normal Electrodiagnostic Studies: Sunderland 'Zero' Ischemic Conduction Block of the Common Peroneal Nerve" by Peters and Colleagues.', Annals of Plastic Surgery, Publish Ahead of Print, http://dx.doi.org/10.1097/sap.0000000000003245
,2022, 'Consensus for experimental design in electromyography (CEDE) project: High-density surface electromyography matrix', Journal of Electromyography and Kinesiology, 64, http://dx.doi.org/10.1016/j.jelekin.2022.102656
,2022, 'Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis', Brain, 145, pp. 1598 - 1609, http://dx.doi.org/10.1093/brain/awac077
,2022, 'Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis', The Lancet Neurology, 21, pp. 465 - 479, http://dx.doi.org/10.1016/S1474-4422(21)00414-2
,2022, 'Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis', The Lancet Neurology, 21, pp. 480 - 493, http://dx.doi.org/10.1016/S1474-4422(21)00465-8
,2022, 'Differences in nerve excitability properties across upper limb sensory and motor axons', Clinical Neurophysiology, 136, pp. 138 - 149, http://dx.doi.org/10.1016/j.clinph.2021.12.006
,2022, 'Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15040433
,2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y
,2022, 'The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis', Brain, 145, pp. 1207 - 1210, http://dx.doi.org/10.1093/brain/awab472
,